Physician profile

James M Jarrett

Internal Medicine · Buckeye, WV

NPI 1841455888

$420.63

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$27.42

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $82.08 2020-2022
Abbvie INC. $72.98 2021-2024
Pfizer INC. $60.28 2019-2021
Janssen Pharmaceuticals, INC $56.68 2019-2021
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $47.62 2021
E.R. Squibb & Sons, L.L.C. $41.00 2019
Astrazeneca Pharmaceuticals LP $33.39 2019-2020
Amarin Pharma, INC. $13.78 2020
Novo Nordisk INC $12.82 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

James M Jarrett

$420.63

in general payments reported 2019-2025

Years
2019-2024
Top company
Novartis Pharmaceuticals Corporation

https://glasscript.com/doctor/83926/james-m-jarrett

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.